IDT Australia Limited (ASX:IDT): Sterile Manufacturing and FY26 Financial Developments

Aditi Sarkar

14 October 2026 08:18 PM AEDT

IDT Australia Limited (ASX:IDT): Sterile Manufacturing and FY26 Financial Developments

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

IDT Australia operates pharmaceutical development and contract manufacturing services across several specialist production areas.
FY26 sales revenue reached $20.357 million, while revenue and other income totalled $20.534 million.
FY26 net loss narrowed to $2.717 million, compared with $8.063 million in the preceding reporting period.
Active pharmaceutical ingredient and specialty oral manufacturing revenues increased, while advanced therapies revenue decreased.
The company announced a proposed $7 million investment in sterile and solid oral manufacturing capabilities.

IDT Australia Limited (ASX:IDT) is a pharmaceutical contract development and manufacturing organisation providing services that help move medicines from development through to production. Its operations cover active pharmaceutical ingredients (APIs), sterile manufacturing and specialist oral dosage forms. FY26 results released on 20 August 2026 outlined changes across these activities, including higher API and oral manufacturing revenue, reduced advanced therapies revenue and plans to upgrade manufacturing capacity.

FY26 Earnings and Revenue Profile

IDT Australia Limited (ASX:IDT) reported sales revenue of $20.357 million for the financial year ended 30 June 2026, compared with $19.217 million in the preceding period. Total revenue and other income reached $20.534 million. The distinction matters because the latter figure incorporates non-sales income and should not be described as sales alone.

The company recorded a loss after tax of $2.717 million for FY26, compared with a loss of $8.063 million in the comparative period. Management also reported EBITDA of negative $922,000, representing an 85.1% improvement year on year. These results describe a smaller operating loss rather than a return to statutory profitability.

Different Outcomes Across Manufacturing Divisions

The segment mix at IDT Australia Limited (ASX:IDT) changed during FY26. API manufacturing revenue increased 44% to $6.9 million. This division handles small-molecule compounds and complex or high-potency chemistry, providing a technical foundation for the company’s contract manufacturing activities.

Specialty oral manufacturing revenue increased 49% to $5.8 million. In contrast, advanced therapies revenue declined 27% to $7.7 million. The three divisions therefore contributed unevenly to the full-year result, underscoring the importance of considering individual manufacturing lines rather than treating all contract development and manufacturing services as a single activity.

Sterile Manufacturing Investment and Capabilities

Sterile manufacturing involves controlling contamination during the production and filling of medicines, including products that require aseptic processing. The supplied article emphasises isolator-based containment and high-potency work; these are technically distinct considerations that must be assessed alongside the company’s disclosed manufacturing investment and regulatory requirements.

In its August 2026 results communication, IDT Australia Limited (ASX:IDT) outlined a $7 million capital investment programme, funded through an existing debt facility, for a new sterile line and upgrades to solid oral manufacturing. The proposed spending connects manufacturing capacity with the company’s stated effort to broaden its specialist contract manufacturing services. It does not, by itself, establish additional completed capacity or regulatory approvals.

FY27 Outlook and Operational Constraints

IDT Australia Limited (ASX:IDT) said it expected positive EBITDA in FY27 and set out a three-year $50 million revenue objective in its August 2026 announcement. These are management targets, not reported FY27 outcomes. The company also increased its annualised cost-savings target to $2.5 million as part of its operating reset.

Execution remains dependent on customer demand, manufacturing utilisation, debt-funded investment and compliance with pharmaceutical production standards. Sterile facilities require validation, controlled processes and ongoing quality oversight. Delivery timing, costs and the allocation of production work may affect how investment translates into reported operating performance.

Key Insights

For IDT Australia Limited (ASX:IDT), FY26 illustrated differing conditions across its production businesses. Higher API and specialty oral revenue coincided with lower advanced therapies revenue and a reduced statutory loss. The proposed sterile line, oral manufacturing upgrades and FY27 EBITDA expectation provide a defined set of disclosed operational milestones. Their financial effects will depend on subsequent delivery and reporting.

FAQs

Q:What does IDT Australia manufacture?

A:It provides pharmaceutical contract development and manufacturing services, including APIs, sterile products and specialist oral formulations.

Q:What sales revenue did IDT report in FY26?

A:Sales revenue was $20.357 million for the year ended 30 June 2026.

Q:Did IDT report a profit for FY26?

A:No. It reported a statutory loss after tax of $2.717 million.

Q:What investment did IDT announce in August 2026?

A:It outlined a $7 million programme for a new sterile line and solid oral manufacturing upgrades.

Q:What was IDT’s FY27 EBITDA outlook?

A:Management stated that it expected positive EBITDA in FY27; this was guidance rather than a reported result.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.